Altimmune, Inc. Reports Third Quarter 2026 Financial Results and $480 million in Cash and Investments

Altimmune, Inc. reported cash, cash equivalents and investments totaling $480 million as of September 30, 2026. The company reported a net loss of $31.6 million, or $0.15 net loss per share, for the three months ended September 30, 2026, compared to a net loss of $19.0 million, o